First Time Loading...

Myovant Sciences Ltd
NYSE:MYOV

Watchlist Manager
Myovant Sciences Ltd Logo
Myovant Sciences Ltd
NYSE:MYOV
Watchlist
Price: 26.98 USD -0.04% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

MYOV's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]

The intrinsic value of one MYOV stock under the Base Case scenario is 6.21 USD. Compared to the current market price of 26.98 USD, Myovant Sciences Ltd is Overvalued by 77%.

Key Points:
MYOV Intrinsic Value
Base Case
6.21 USD
Overvaluation 77%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Myovant Sciences Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MYOV stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Myovant Sciences Ltd

Provide an overview of the primary business activities
of Myovant Sciences Ltd.

What unique competitive advantages
does Myovant Sciences Ltd hold over its rivals?

What risks and challenges
does Myovant Sciences Ltd face in the near future?

Has there been any significant insider trading activity
in Myovant Sciences Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Myovant Sciences Ltd.

Provide P/S
for Myovant Sciences Ltd.

Provide P/E
for Myovant Sciences Ltd.

Provide P/OCF
for Myovant Sciences Ltd.

Provide P/FCFE
for Myovant Sciences Ltd.

Provide P/B
for Myovant Sciences Ltd.

Provide EV/S
for Myovant Sciences Ltd.

Provide EV/GP
for Myovant Sciences Ltd.

Provide EV/EBITDA
for Myovant Sciences Ltd.

Provide EV/EBIT
for Myovant Sciences Ltd.

Provide EV/OCF
for Myovant Sciences Ltd.

Provide EV/FCFF
for Myovant Sciences Ltd.

Provide EV/IC
for Myovant Sciences Ltd.

Show me price targets
for Myovant Sciences Ltd made by professional analysts.

What are the Revenue projections
for Myovant Sciences Ltd?

How accurate were the past Revenue estimates
for Myovant Sciences Ltd?

What are the Net Income projections
for Myovant Sciences Ltd?

How accurate were the past Net Income estimates
for Myovant Sciences Ltd?

What are the EPS projections
for Myovant Sciences Ltd?

How accurate were the past EPS estimates
for Myovant Sciences Ltd?

What are the EBIT projections
for Myovant Sciences Ltd?

How accurate were the past EBIT estimates
for Myovant Sciences Ltd?

Compare the revenue forecasts
for Myovant Sciences Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Myovant Sciences Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Myovant Sciences Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Myovant Sciences Ltd compared to its peers.

Compare the P/E ratios
of Myovant Sciences Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Myovant Sciences Ltd with its peers.

Analyze the financial leverage
of Myovant Sciences Ltd compared to its main competitors.

Show all profitability ratios
for Myovant Sciences Ltd.

Provide ROE
for Myovant Sciences Ltd.

Provide ROA
for Myovant Sciences Ltd.

Provide ROIC
for Myovant Sciences Ltd.

Provide ROCE
for Myovant Sciences Ltd.

Provide Gross Margin
for Myovant Sciences Ltd.

Provide Operating Margin
for Myovant Sciences Ltd.

Provide Net Margin
for Myovant Sciences Ltd.

Provide FCF Margin
for Myovant Sciences Ltd.

Show all solvency ratios
for Myovant Sciences Ltd.

Provide D/E Ratio
for Myovant Sciences Ltd.

Provide D/A Ratio
for Myovant Sciences Ltd.

Provide Interest Coverage Ratio
for Myovant Sciences Ltd.

Provide Altman Z-Score Ratio
for Myovant Sciences Ltd.

Provide Quick Ratio
for Myovant Sciences Ltd.

Provide Current Ratio
for Myovant Sciences Ltd.

Provide Cash Ratio
for Myovant Sciences Ltd.

What is the historical Revenue growth
over the last 5 years for Myovant Sciences Ltd?

What is the historical Net Income growth
over the last 5 years for Myovant Sciences Ltd?

What is the current Free Cash Flow
of Myovant Sciences Ltd?

Financials

Balance Sheet Decomposition
Myovant Sciences Ltd

Current Assets 386.6m
Cash & Short-Term Investments 274.4m
Receivables 44m
Other Current Assets 68.1m
Non-Current Assets 16.9m
PP&E 9.6m
Other Non-Current Assets 7.3m
Current Liabilities 245.8m
Accounts Payable 12.2m
Accrued Liabilities 90m
Other Current Liabilities 143.5m
Non-Current Liabilities 715.9m
Long-Term Debt 358.7m
Other Non-Current Liabilities 357.2m
Efficiency

Earnings Waterfall
Myovant Sciences Ltd

Revenue
379.1m USD
Cost of Revenue
-102.3m USD
Gross Profit
276.9m USD
Operating Expenses
-423.8m USD
Operating Income
-146.9m USD
Other Expenses
-36.9m USD
Net Income
-183.8m USD

Free Cash Flow Analysis
Myovant Sciences Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MYOV Profitability Score
Profitability Due Diligence

Myovant Sciences Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Negative Free Cash Flow
Exceptional Revenue Growth Forecast
Positive Gross Profit
55/100
Profitability
Score

Myovant Sciences Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

MYOV Solvency Score
Solvency Due Diligence

Myovant Sciences Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
45/100
Solvency
Score

Myovant Sciences Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MYOV Price Targets Summary
Myovant Sciences Ltd

There are no price targets for MYOV.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MYOV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MYOV Price
Myovant Sciences Ltd

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
+54%
5Y 5Y
+41%
10Y 10Y
+103%
Annual Price Range
26.98
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return 3.8%
Standard Deviation of Annual Returns 56.07%
Max Drawdown -78%
Shares Statistics
Market Capitalization 2.6B USD
Shares Outstanding 97 259 504
Percentage of Shares Shorted 17.9%

MYOV Return Decomposition
Main factors of price return

What is price return decomposition?

MYOV News

Last Important Events
Myovant Sciences Ltd

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Myovant Sciences Ltd

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Myovant Sciences Ltd Logo
Myovant Sciences Ltd

Country

United Kingdom

Industry

Biotechnology

Market Cap

2.6B USD

Dividend Yield

0%

Description

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company’s two products include ORGOVYX, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The company through its subsidiary, Myovant Sciences GmbH developing supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company is developing Relugolix for the treatment of men with advanced prostate cancer. The company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.

Contact

London
Ste 1 3rd Fl, 11/12 St. James's Square
+442074003351.0
http://myovant.com/

IPO

2016-10-27

Employees

407

Officers

CEO & Director
Mr. David C. Marek
Principal Financial Officer
Mr. Uneek Mehra
Chief Commercial Officer
Ms. Lauren Merendino
Gen. Counsel & Corp. Sec.
Mr. Matthew Lang J.D.
Director of Corp. Communications
Mr. Albert Liao
Sr. VP of HR
Ms. Ann Tomlin
Show More
Sr. VP of Product Devel.
Mr. Bryan Selby
Chief Medical Officer
Dr. Juan Camilo Arjona Ferreira M.D.
Head of Drug Safety & Pharmacovigilance
Dr. Andria Langenberg M.D.
Sr. VP of Pharmaceutical Operations & Devel.
Mr. Jeffrey D. Nornhold
Show Less

See Also

Discover More
What is the Intrinsic Value of one MYOV stock?

The intrinsic value of one MYOV stock under the Base Case scenario is 6.21 USD.

Is MYOV stock undervalued or overvalued?

Compared to the current market price of 26.98 USD, Myovant Sciences Ltd is Overvalued by 77%.